Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Nephrol ; 31(1): 119-127, 2018 02.
Article in English | MEDLINE | ID: mdl-28205136

ABSTRACT

In 2013, the Italian Society of Nephrology joined forces with Nephrocare-Italy to create a clinical research cohort of patients on file in the data-rich clinical management system (EUCLID) of this organization for the performance of observational studies in the hemodialysis (HD) population. To see whether patients in EUCLID are representative of the HD population in Italy, we set out to compare the whole EUCLID population with patients included in the regional HD registries in Emilia-Romagna (Northern Italy) and in Calabria (Southern Italy), the sole regions in Italy which have systematically collected an enlarged clinical data set allowing comparison with the data-rich EUCLID system. An analysis of prevalent and incident patients in 2010 and 2011 showed that EUCLID patients had a lower prevalence of coronary heart disease, peripheral vascular disease, heart failure, valvular heart disease, liver disease, peptic ulcer and other comorbidities and risk factors and a higher fractional urea clearance (Kt/V) than those in the Emilia Romagna and Calabria registries. Accordingly, survival analysis showed a lower mortality risk in the EUCLID 2010 and 2011 cohorts than in the combined two regional registries in the corresponding years: for 2010, hazard ratio (HR) EUCLID vs. Regional registries: 0.80 [95% confidence interval: 0.71-0.90]; for 2011, HR: 0.76 [0.65-0.90]. However, this difference was nullified by statistical adjustment for the difference in comorbidities and risk factors, indicating that the longer survival in the EUCLID database was attributable to the lower risk profile of patients included in that database. This preliminary analysis sets the stage for future observational studies and indicates that appropriate adjustment for difference in comorbidities and risk factors is needed to generalize to the Italian HD population analyses based on the data-rich EUCLID database.


Subject(s)
For-Profit Insurance Plans , Kidney Diseases/therapy , Process Assessment, Health Care , Renal Dialysis/adverse effects , Aged , Comorbidity , Databases, Factual , Female , Health Services Research , Health Status , Humans , Incidence , Italy/epidemiology , Kidney Diseases/diagnosis , Kidney Diseases/economics , Kidney Diseases/mortality , Male , Middle Aged , Prevalence , Process Assessment, Health Care/economics , Registries , Renal Dialysis/economics , Renal Dialysis/mortality , Risk Factors , Time Factors , Treatment Outcome
2.
BMC Med Genet ; 18(1): 10, 2017 Feb 01.
Article in English | MEDLINE | ID: mdl-28143435

ABSTRACT

BACKGROUND: Bardet-Biedl syndrome (BBS) is a rare genetic disorder that features retinal degeneration, obesity, polydactyly, learning disabilities and renal abnormalities. The diagnosis is often missed at birth, the median age at diagnosis being 9 years. In the attempt to shed light on BBS and improve its diagnosis and treatment, we evaluated the genotype-phenotype relationship in patients with a molecular diagnosis of BBS. METHODS: We analyzed three common BBS genes, BBS1, BBS10 and BBS2, in 25 Italian patients fulfilling the clinical criteria of BBS. In 12 patients, we identified gene-specific biallelic variants and thus correlated genotype to the ophthalmic, renal and audio-vestibular phenotypes. RESULTS: At least one sequence variant was found in 60% of patients. The most common mutated gene was BBS1 followed by BBS10. Of the 17 sequence variants we found, 11 have not previously been associated with BBS. In 12 patients, we identified biallelic pathogenic variants; they had retinitis pigmentosa with early onset of visual impairment. However, retinal dystrophy was less severe in patients with BBS1 than in those with BBS10 variants. Overall, we found a high prevalence of renal dysmorphism and dysfunction. Notably, patients with BBS10 variants had the most severe renal impairment, which resulted in a critical decline in renal function. All the patients who underwent audio-vestibular evaluation had dysfunction of the cochlear outer hair cells, thus confirming the presence of hearing defects. CONCLUSION: BBS1, BBS2 and BBS10 are major causative genes in Italian BBS patients. BBS10 was associated with the worse outcome in terms of the renal, ocular and audiovestibular phenotypes. Cochlear dysfunction should be included among the hallmarks of BBS.


Subject(s)
Bardet-Biedl Syndrome/genetics , Eye/physiopathology , Kidney/physiopathology , White People/genetics , Adolescent , Adult , Aged , Auditory Threshold , Bardet-Biedl Syndrome/pathology , Chaperonins , Child , DNA/chemistry , DNA/isolation & purification , DNA/metabolism , DNA Mutational Analysis , Eye/diagnostic imaging , Female , Genetic Association Studies , Genotype , Group II Chaperonins/genetics , Humans , Italy , Male , Microtubule-Associated Proteins/genetics , Middle Aged , Phenotype , Polymorphism, Genetic , Proteins/genetics , Tomography, Optical Coherence , Young Adult
3.
G Ital Nefrol ; 30(2)2013.
Article in Italian | MEDLINE | ID: mdl-23832454

ABSTRACT

Hydrogen sulfide, (H2S), is an endogenous gas which exerts a protective function in several biological processes, including those involved in inflammation, blood pressure regulation, and energy metabolism. The enzymes involved in H2S production are cysthationine -synthetase, cysthationine -lyase and 3-mercaptopyruvate sulfurtransferase. Low plasma H2S levels have been found in chronic renal failure (CRF) in both humans and animal models. The mechanisms leading to H2S deficiency in CRF are linked to reduced gene expression of cysthationine -lyase. Intense research is currently under way to discover the link between low H2S levels, CRF progression and the uremic syndrome and to determine whether therapeutic interventions aimed at increasing H2S levels might benefit these patients.


Subject(s)
Hydrogen Sulfide/metabolism , Kidney Failure, Chronic/physiopathology , Lyases/physiology , Vasodilation/physiology , Animals , Apoptosis , Apoptosis Regulatory Proteins/biosynthesis , Apoptosis Regulatory Proteins/genetics , Blood Pressure/physiology , Cardiovascular Diseases/physiopathology , Cells, Cultured , Cysteine/metabolism , Disease Progression , Enzyme Induction , Homocysteine/metabolism , Humans , Inflammation , Kidney/metabolism , Kidney/physiopathology , Lipid Peroxidation , Lyases/biosynthesis , Lyases/genetics , Mice , Mice, Knockout , Oxidative Stress , Rats
4.
J Med Case Rep ; 6: 417, 2012 Dec 11.
Article in English | MEDLINE | ID: mdl-23232027

ABSTRACT

INTRODUCTION: In the treatment of secondary hyperparathyroidism of chronic kidney disease, calcimimetics - allosteric modulators of the calcium-sensing receptor - inhibit glandular hyperplasia and significantly reduce circulating parathyroid hormone levels. They have a major impact on the management of secondary hyperparathyroidism. CASE PRESENTATION: We present the clinical case of a 41-year-old Caucasian man undergoing chronic hemodialysis, who had a parathyroidectomy to treat severe secondary hyperparathyroidism resistant to cinacalcet treatment. Preoperatively, 24 months after high-dose cinacalcet hydrochloride, we observed a persistently elevated intact parathyroid hormone serum level, and detected clear parathyroid gland hyperplasia regression on ultrasound. We performed a three-gland parathyroidectomy, which was assumed to be total, associated with a hemithyroidectomy. Our patient then entered a hypoparathyroid state. A histopathological examination showed that the removed parathyroid glands were of small size, with a total weight of 1g, associated with a multifocal small papillary thyroid cancer. CONCLUSION: In the management of secondary hyperparathyroidism, cinacalcet hydrochloride effectively reduces total parathyroid gland hyperplasia. However, a persisting elevated intact parathyroid hormone serum level may be observed, demonstrating that reduced parathyroid hyperplastic tissue may still be associated with severe secondary hyperparathyroidism. Even if calcimimetics are very effective in secondary hyperparathyroidism treatment, further studies are necessary for a better understanding of their actions.

5.
PLoS One ; 7(12): e52014, 2012.
Article in English | MEDLINE | ID: mdl-23284854

ABSTRACT

The CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) activity and localization are influenced by the cytoskeleton, in particular by actin and its polymerization state. In this study we investigated whether the expression of the hypertensive mutations of α-adducin (G460W-S586C in humans, F316Y in rats), an actin capping protein, led to a functional modification of CFTR activity and surface expression. The experiments were performed on HEK293 T cells cotransfected with CFTR and the human wild type (WT) or G460W mutated α-adducin. In whole-cell patch-clamp experiments, both the CFTR chloride current and the slope of current activation after forskolin addition were significantly higher in HEK cells overexpressing the G460W adducin. A higher plasma membrane density of active CFTR channels was confirmed by cell-attached patch-clamp experiments, both in HEK cells and in cultured primary DCT cells, isolated from MHS (Milan Hypertensive Strain, a Wistar rat (Rattus norvegicus) hypertensive model carrying the F316Y adducin mutation), compared to MNS (Milan Normotensive Strain) rats. Western blot experiments demonstrated an increase of the plasma membrane CFTR protein expression, with a modification of the channel glycosylation state, in the presence of the mutated adducin. A higher retention of CFTR protein in the plasma membrane was confirmed both by FRAP (Fluorescence Recovery After Photobleaching) and photoactivation experiments. The present data indicate that in HEK cells and in isolated DCT cells the presence of the G460W-S586C hypertensive variant of adducin increases CFTR channel activity, possibly by altering its membrane turnover and inducing a retention of the channel in the plasmamembrane. Since CFTR is known to modulate the activity of many others transport systems, the increased surface expression of the channel could have consequences on the whole network of transport in kidney cells.


Subject(s)
Calmodulin-Binding Proteins/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Hypertension/genetics , Hypertension/metabolism , Kidney Tubules, Distal/metabolism , Mutation , Animals , Cell Membrane/metabolism , Cells, Cultured , Disease Models, Animal , Gene Expression , HEK293 Cells , Humans , Male , Patch-Clamp Techniques , Protein Binding , Rats , Signal Transduction
6.
Hum Mol Genet ; 19(14): 2792-803, 2010 Jul 15.
Article in English | MEDLINE | ID: mdl-20444807

ABSTRACT

The oral-facial-digital type I syndrome (OFDI; MIM 311200) is a rare syndromic form of inherited renal cystic disease. It is transmitted as an X-linked dominant, male lethal disorder and is caused by mutations in the OFD1 gene. Previous studies demonstrated that OFDI belongs to the growing number of disorders ascribed to dysfunction of primary cilia. We generated a conditional inactivation of the mouse Ofd1 gene using the Ksp-Cre transgenic line, which resulted in a viable model characterized by renal cystic disease and progressive impairment of renal function. The study of this model allowed us to demonstrate that primary cilia initially form and then disappear after the development of cysts, suggesting that the absence of primary cilia is a consequence rather than the primary cause of renal cystic disease. Immunofluorescence and western blotting analysis revealed upregulation of the mTOR pathway in both dilated and non-dilated renal structures. Treatment with rapamycin, a specific inhibitor of the mTOR pathway, resulted in a significant reduction in the number and size of renal cysts and a decrease in the cystic index compared with untreated mutant animals, suggesting that dysregulation of this pathway in our model is mTOR-dependent. The animal model we have generated could thus represent a valuable tool to understand the molecular link between mTOR and cyst development, and eventually to the identification of novel drug targets for renal cystic disease.


Subject(s)
Gene Silencing/physiology , Intracellular Signaling Peptides and Proteins/metabolism , Kidney Diseases, Cystic/genetics , Kidney/metabolism , Protein Serine-Threonine Kinases/metabolism , Proteins/genetics , Animals , Cells, Cultured , Cilia/genetics , Cilia/metabolism , Disease Progression , Dogs , Epithelial Cells/metabolism , Epithelial Cells/pathology , Female , Intracellular Signaling Peptides and Proteins/genetics , Intracellular Signaling Peptides and Proteins/physiology , Kidney/pathology , Kidney Diseases, Cystic/metabolism , Kidney Diseases, Cystic/pathology , Male , Mice , Mice, Transgenic , Organ Specificity/genetics , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/physiology , Proteins/antagonists & inhibitors , Proteins/metabolism , Signal Transduction/physiology , TOR Serine-Threonine Kinases , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...